Genmab A (GMAB) Asset Utilization Ratio (2019 - 2026)
Genmab A's (GMAB) quarterly Asset Utilization Ratio came in at 0.51 in Q2 2026, down 43.88% on a YoY basis from 0.91 in Q2 2025, and up 8.99% quarter-over-quarter from 0.47 in Q1 2026.
Powered by 
Analysis
Genmab A (GMAB) Asset Utilization Ratio (2019 - 2026) Analysis & Trends
Genmab A (GMAB) has reported Asset Utilization Ratio for 8 consecutive years, with 0.51 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Asset Utilization Ratio fell 43.88% year-over-year to 0.51; the trailing twelve-month figure through Jun 2026 stood at 0.51 (down 43.88% YoY), and the FY2025 full-year result was 0.38, changed N/A from the prior year.
- Asset Utilization Ratio grew to 0.51 in Q2 2026 per GMAB's latest filing, from 0.47 in the prior quarter.
- Across five years, Asset Utilization Ratio topped out at 2.41 in Q3 2023 and bottomed at 1.41 in Q3 2024.
- Historically, Asset Utilization Ratio has averaged 0.34 across 5 years, with a median of 0.51 in 2026.
- The sharpest annual moves came in 2024 and 2025: Asset Utilization Ratio slumped 158.38% in 2024, then surged 239.16% in 2025.
- Over 5 years, Asset Utilization Ratio stood at 1.13 in 2022, then slumped by 210.84% to 1.25 in 2023, then dropped by 12.44% to 1.41 in 2024, then soared by 239.16% to 1.96 in 2025, then slumped by 73.93% to 0.51 in 2026.
- According to Business Quant data, Asset Utilization Ratio over the past three periods registered 0.51, 0.47, and 1.96 for Q2 2026, Q1 2026, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn | 0.40 |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn | 0.58 |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn | 0.47 |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn | 0.38 |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn | 0.20 |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn | - |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn | 0.90 |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn | 0.33 |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn | 0.00 |
| 10 | Genmab A | 2.23 Bn | 728.64 Mn | 1.07 Bn | 0.51 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 0.51 |
| Mar 31, 2026 | 0.47 |
| Sep 30, 2025 | 1.96 |
| Jun 30, 2025 | 0.91 |
| Mar 31, 2025 | 0.90 |
| Sep 30, 2024 | -1.41 |
| Jun 30, 2024 | -0.75 |
| Mar 31, 2024 | -1.09 |
| Dec 31, 2023 | -1.25 |
| Sep 30, 2023 | 2.41 |
| Jun 30, 2022 | 1.13 |
| Dec 31, 2021 | 1.20 |
| Sep 30, 2021 | 1.17 |
| Jun 30, 2021 | 0.54 |
| Dec 31, 2020 | 0.10 |
| Sep 30, 2020 | 0.14 |
| Dec 31, 2019 | 0.23 |